

# ALPIC 2022

**Advanced Learning on Platelets  
& Thrombosis International Course**

**4-6 November 2022**

**Kalavrita Canyon Hotel**

**KALAVRITA-GREECE**

## **Alexandros Tselepis**

Professor  
of Biochemistry-Clinical  
Chemistry, Department  
of Chemistry, University  
of Ioannina

## **Course Directors:**

### **John Goudevenos**

Emeritus Professor of  
Internal Medicine-Cardiology,  
Faculty of Medicine,  
School of Health Sciences,  
University of Ioannina

### **Haralampos Milionis**

Professor of Internal  
Medicine, Faculty  
of Medicine, School of Health  
Sciences, University  
of Ioannina

## **Organizer:**



European and Mediterranean League  
Against Thrombotic Diseases

The Congress will be accredited  
with **21 C.M.E. Credits**  
by the Panhellenic Medical Association

**Scientific Program**

## Η ΔΙΚΗ ΣΑΣ ΠΡΟΝΟΗΤΙΚΟΤΗΤΑ ΠΡΟΔΙΑΓΡΑΦΕΙ ΤΟ ΜΕΛΛΟΝ ΤΟΥ



**ΣΕ ΠΕΡΙΣΤΑΤΙΚΑ**  
ΜΒΚΜ<sup>1</sup> ABLATION<sup>1\*</sup> post PCI<sup>2\*\*</sup>

**Ασθενής με μη Βαλβιδική  
Κολπική Μαρμαρυγή**

 <b>150 mg BID</b> Κύρια δοσολογία	 <b>110 mg BID</b> Ασθενείς ηλικίας ≥ 80 ετών ή συγχρηρήση με βεραπαμίλη ή αυξημένος αιμορραγικός κίνδυνος
--	---

**Pradaxa®**  
dabigatran etexilate

**Praxbind®**  
idarucizumab

Κλείνοντας τον κύκλο

1. Calkins H et al. - NEJM 2017 Apr 27;376:1627-1636. 2. Cannon CP et al NEJM 2017 Oct 19, 377(16):1513-1524.  
3. Περιλήψη Χαρακτηριστικών Προϊόντος Pradaxa® 4. Περιλήψη Χαρακτηριστικών Προϊόντος Praxbind®.

Για τις εγκεκριμένες ενδείξεις, τις ανεπιθύμητες ενέργειες, τις προειδοποιήσεις, τις αντενδείξεις, τις αναφορές πληροφοριών παρακολούθησης ανατρέξτε στην Περιλήψη Χαρακτηριστικών Προϊόντος που διατίθεται από την εταιρία. Πριν τη συνταγογράφηση συμβουλευτείτε την ΠΧΠ που διατίθεται στο εκθετήριο ή στο QR code.

\* Μη Βαλβιδική κολπική μαρμαρυγή.

\*\* RE-CIRCUIT: αβολόγηση την ασφαλή της χωρίς διακοπή θεραπείας με δαβιγατράνη 150 mg BID σε ασθενείς με ΚΜ που υποβάλλονται σε κατάλυση.

\*\* RE-DUAL PCI: αβολόγηση την ασφαλή δύο ασυμπτών διπλής θεραπείας με δαβιγατράνη 110 mg και 150 mg BID χωρίς ασπρήνη έναντι της καθεραμής τριπλής σιγανής με βαρφαρίνη.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή

Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπεριλαμβανόμενες την  
«HITRINK KAPTA»

**ΚΑΤΟΧΟΣ ΤΗΣ ΔΕΛΤΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:**Boehringer Ingelheim International GmbH, Binger Str. 173, 55216 Ingelheim am Rhein, Γερμανία. **ΑΡΙΘΜΟΣ(ΟΙ) ΔΕΛΤΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** PRADAXA®: EU/1/08/442/001. PRAXBIND®: EU/1/10/1054/001. **ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ/ΑΝΑΘΕΣΗΣ ΤΗΣ ΔΕΛΤΙΑΣ:** PRADAXA®: Ημερομηνία πρώτης έγκρισης: 18 Μαρτίου 2008. Ημερομηνία τελευταίας ανανέωσης: 08 Ιανουαρίου 2018. PRAXBIND®: Ημερομηνία πρώτης έγκρισης: 20 Νοεμβρίου 2015. Ημερομηνία τελευταίας ανανέωσης: 17 Σεπτεμβρίου 2020. **ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** PRADAXA®: 20/01/2020. PRAXBIND®: 17/09/2020. **PRADAXA CAPS 110 MG/CAP 6ΤΔ60 (σε BLISTERS/ALU/ALU)** κωδικός: 45.45 € Α.Τ. 66.45 €. **PRADAXA CAPS 150 MG/CAP 1 Φιάλη (PP)** κωδικός: 45.45 € Α.Τ. 66.45 €. **PRADAXA CAPS 150MG/CAP 6ΤΔ60 (σε BLISTERS/ALU/ALU)** κωδικός: 46.27 € Α.Τ. 67.65 €. **PRADAXA CAPS 150MG/CAP 1 Φιάλη (PP)** κωδικός: 46.27 € Α.Τ. 67.65 €. **PRADAXA CAPS 72MG/CAP 6ΤΔ60 (σε BLISTERS/ALU/ALU)** κωδικός: 46.27 € Α.Τ. 67.65 €. **Praxbind 2.5 g/50 ml, Δόλωμα:** NT.2.203.37 € Α.Τ.2.701.93 €. **Χρησιμοποιήστε με ασφάλεια τον/τα σκάν/ες.**



## WELCOME MESSAGE

*Dear Colleagues,*

We are pleased to welcome you to **ALPIC 2022** (Advanced Learning on Platelets & Thrombosis International Course), the 12<sup>th</sup> international scientific event on Platelets and Thrombosis, taking place this year in **Kalavrita**, Peloponnese, Greece, at Kalavrita Canyon Hotel, on **4-6 November, 2022**. ALPIC 2022 is organized by the European and Mediterranean League against Thrombotic Diseases (EMLTD), having as Course Directors Professors A. Tselepis, I. Goudevenos and H. Milionis. The Course aims to serve as a knowledge transfer forum for scientists in the current aspects of Platelet and Thrombosis research, ranging from the basic science to the clinical practice. The scientific program is designed to highlight the rapid development and ongoing evolution on the mechanisms underlying Thrombosis and Haemostasis along with discussion regarding all current advances in Antiplatelet and Anticoagulant therapy. We are proud that ALPIC has gained worldwide warm acceptance and recognition for its scientific merit and we do hope that ALPIC 2022 will further strengthen the European and Mediterranean network for Thrombosis in both basic research and clinical practice. ALPIC 2022 is organized with the contribution of our hosting partners, the Atherothrombosis Research Centre of the University of Ioannina and the Institute for the Study and Education on Thrombosis and Antithrombotic Therapy, which will give us the opportunity to bring together scientists and experts having a wide spectrum of disciplines, who will share current knowledge on various aspects of Thrombosis. The course local organizing committee consisted of University Professors with different specialties has created an attractive and comprehensive scientific programme with care and appreciation for attendees' scientific and personal enjoyment. An internationally recognized panel of invited speakers will present state of the art lectures and will create an excellent opportunity for all participants to stimulate an extended and very constructive discussion both inside and outside the lecture hall.

The dreamy setting with picturesque squares, stone-paved streets and cute little houses of Kalavrita will welcome ALPIC 2022. Kalavrita is a town, a province and a municipality in the East Central part of the prefecture of Achaia. The historic town of Kalavrita, one of the most exciting destinations of Peloponnese, will add to the scientific quality of the presentations, making this event a remarkable one for all participants. The Organizers will spare no efforts to ensure that ALPIC 2022 will be an exciting and enriching experience for all participants. We welcome you and we wish you all enjoy ALPIC 2022 in the picturesque landscape offered by Kalavrita and its mountainous landscape.

With our best regards,

The ALPIC 2021 Course Directors

**Prof. Alexandros Tselepis   Prof. Ioannis Goudevenos   Prof. Haralampos Milionis**

## ALPIC ORGANIZER

### ■ Organizer:

---



European and Mediterranean League  
Against Thrombotic Diseases

### ■ Course Directors:

---

#### **Alexandros Tselepis**

Professor of Biochemistry  
- Clinical Chemistry  
Department of Chemistry,  
University of Ioannina

#### **John Goudevenos**

Emeritus Professor  
of Internal Medicine  
Cardiology, Faculty of  
Medicine, School of  
Health Sciences  
University of Ioannina

#### **Haralampos Milionis**

Professor of Internal  
Medicine, Faculty  
of Medicine, School  
of Health Sciences,  
University of Ioannina

### **Here's why! See you in Kalavrita for what promises to be a most exciting congress!**

The ALPIC 2022 scientific program is focused on realistic views of controversial issues in thrombosis and antithrombotic therapy. Sessions include a combination of Keynote lectures, Clinical Seminars Plenary Sessions, Debates, Meet the Experts Sessions presented by a faculty of internationally renowned leaders.

Friday, November 4<sup>th</sup>, 2022

11.00 **Registrations**

11.30-13.30 **The Most Impactful Antithrombotic Trials in 2021-2022**

*Chairs:* Stratis **Pattakos**, Dimitrios **Alexopoulos**

HEP-COVID

Matilda **Florentin**

MICHELLE, Μελέτη INVICTUS

Theodora **Babali**

REMAP-CAP, ACTIV-4a, and ATTACC

Georgia **Kaiafa**

MASTER DAPT

Dimitrios **Nikas**

ADAPT-TAVR

Georgios **Almpanis**

STOPDAPT-2 ACS

Dimitrios **Alexopoulos**

IMPROVE VTE (Hospitalized medically ill patients)

Ioannis **Koulas**

PACIFIC Program (AF, AMI, STROKE)

John **Goudevenos**

## SCIENTIFIC PROGRAMME

Friday, November 4<sup>th</sup>, 2022

### 13.30-14.30 **Meet the Experts: From ACS to chronic coronary artery disease. The transition period**

Chairs: Georgios **Kochiadakis**, Dimitrios **Alexopoulos**

P2Y12 Monotherapy following PCI. An alternative approach  
Dimitrios **Alexopoulos**

Dual anti platelet therapy duration? Very short or very long?  
John **Kanakakis**

Very low dose of rivaroxaban. It is time for a new era  
in antithrombotic treatment?  
Christos **Katsouras**

The bleeding risk. The true game changer?  
Georgios **Almpanis**

---

14.30-15.30 **Break**

---

### 15.30-16.30 **Interactive Workshop. Real-World Data on Thrombosis Incidence and Treatment in Countries Affiliated to EMLTD**

Chairs: Vittorio **Pengo** (Italy), Alexandros **Tselepis**

Croatia: Ana **Bronic**

Greece: Dimitrios **Alexopoulos**

Israel: David **Varon**

Portugal: Joao **Morais**

France: Ismail **Elalamy**

Slovenia: Matija **Kozak**

Spain: Lina **Badimon**

### 16.30-17.00 **Antithrombotic Therapy in cardiac Operations**

Chair: John **Goudevenos**

Antithrombotic therapy of patients undergoing noncardiac  
operations according to 2022 ESC guidelines  
Michail **Botis**

Antithrombotic Therapy in Patients Undergoing Transcatheter  
interventions for Structural Heart Disease  
Gregoris **Pattakos**

Friday, November 4<sup>th</sup>, 2022

17.00-17.30 **Coffee Break**

17.30-19.00 **Plenary Session. Stroke therapeutics: an update**

*Chairs:* Georgios **Tsivgoulis**, John **Ellul**

Tenecteplase vs alteplase for iv thrombolysis in Acute Ischemic Stroke  
Georgios **Tsivgoulis**

Safety and efficacy of iv thrombolysis in COVID-19 era  
Eleni **Bakola**

Combination of antiplatelets and anticoagulants for secondary stroke prevention  
Lina **Palaodimou**

Inhibition of factor XI: a new therapeutic horizon for secondary stroke prevention  
John **Ellul**

Inflammation: a new therapeutic target for atherothrombotic stroke prevention  
Odysseas **Kargiotis**

19.00-20.00 **Plenary Session. Cardiovascular complications in cancer patients**

*Chairs:* Nikos **Tsoukalas**, Dimitrios **Alexopoulos**

*Discussant:* Katerina **Panteli**

Evolving data on cardiovascular complications in cancer  
Nikos **Tsoukalas**

Venous Thromboembolism and Risk Stratification in Hematological Malignancies  
Georgia **Kaiafa**

Cardiotoxicity of Cardiovascular drugs. Focus on antithrombotics  
Alexandros **Tselepis**

Optimizing antithrombotic therapy for atrial fibrillation in cancer  
Georgios **Andrikopoulos**

## SCIENTIFIC PROGRAMME

Friday, November 4<sup>th</sup>, 2022

### 20.20-20.45 Official Opening of ALPIC 2022

*Chairs:* Alexandros **Tselepis**, John **Goudevenos**, Haralampos **Milionis**

Vice Rector of the University of Ioannina  
Minas **Paschopoulos**

President of the EMLTD Society  
Alexandros **Tselepis**

President of the Hellenic Cardiological Society  
John **Kanakakis**

Mayor of Kalavrita  
Athanasios **Papadopoulos**

Respected Metropolitan of Kalavrita  
**Ieronimos**

### 20.45-21.10 Opening Lecture

*Chair:* Alexandros **Tselepis**

Deep Learning and Artificial Intelligence  
Panos **Vardas**

---

21.30 **Dinner**

---



Saturday, November 5<sup>th</sup>, 2022

08.30-10.00 **Atrial fibrillation and the Prothrombotic state:  
New insights for 2021-2022**

*Chairs:* Dimitrios **Richter**, Kostas **Pappas**

Prothrombotic conditions and Stroke  
Georgia **Kaifa**

Stroke risk assessment in AF: Simplicity and practicality matter  
Dimitrios **Richter**

Biomarkers for risk stratification in AF  
Stylianos **Tzeis**

Bleeding risk assessment: Its appropriate use  
and inappropriate mis-use  
Vitorio **Pengo**

---

10.00-10.30 **Coffee Break**

---

10.30-11.30 **How to Treat Session. Practical Guidance  
in Antithrombotic Therapy**

*Moderators:* John **Goudevenos**, Anastasios **Spanos**

A 35 year-old woman diagnosed with unprovoked DVT.  
How far should we extend the antithrombotic treatment?  
Kalliroi **Kalantzi**

A 72 year old patient with colonic cancer and pulmonary embolism  
Stavroula **Tsiara**

A 70 Years Old Patient with Atrial Fibrillation on DOAC and Melena  
Athanasios **Pipilis**

Stroke management in COVID-19 patients in the Internal  
Medicine Unit of a Reference Hospital  
Christos **Savopoulos**

11.30-12.00 **Satellite Lecture**

(see page 15)

## SCIENTIFIC PROGRAMME

Saturday, November 5<sup>th</sup>, 2022

**12.00-13.00 Meet the Experts session: Unaddressed issues in Thrombosis and Haemostasis**

*Chairs:* Efrosyni **Nomikou**, Elias **Kyriakou**

Superficial vein thrombosis: Pathophysiology, risk factors and treatment rationale

Fotios **Girtovitis**

Diagnostic and therapeutic approach to a bleeding patient with normal routine coagulation tests

Despina **Adamidou**

**13.00-14.30 Clinical Seminar. Management of acute ischemic stroke**

*Chairs:* Haralampos **Milionis**, Eleni **Koromboki**

Organize admission and triage

Konstantinos **Vemmos**

Dissolve thrombus. What to expect?

Dimitris **Sagris**

Retrieving emboli. Where do we stand?

Panagiotis **Papanagiotou**

---

14.30-15.30 **Break**

---

**15.30-17.00 Meet the Experts. Management of thrombosis at unusual sites. Which antithrombotic and for how long?**

*Chairs:* James **Douketis**, Athanasios **Giannoukas**

*Discussants:* Elissavet **Grouzi**, Konstantinos **Vemmos**,  
Evangelos **Dimakakos**

Cerebral sinus thrombosis

Konstantinos **Vemmos**

Splanchnic thrombosis

Georgios **Glantzounis**

Upper extremity thrombosis

Athanasios **Gianoukas**

Saturday, November 5<sup>th</sup>, 2022

17.00-17.30 **Keynote Lecture**

*Chair:* Alexandros **Tselepis**

Remote monitoring of cardiometabolic disease patients  
Apostolos **Pappas**

17.30-18.00 **Coffee Break**

18.00-20.00 **Plenary Session. Cardiometabolic Risk Factors and Thrombosis. From Pathophysiology to Therapy**

*A joint session of EMLTD with Hellenic Atherosclerosis Society*

*Chairs:* Alexandros **Tselepis**, Evangelos **Liberopoulos**

Major dietary patterns and atherothrombotic disease;  
from epidemiology to clinical practice  
Demosthenes **Panagiotakos**

Postprandial dysmetabolism - A daily stressor of platelets?  
Tzortzis **Nomikos**

"GLP-1 receptor agonists and stroke primary prevention"  
Theodosios **Philippatos**

Metabolic Syndrome – Diabetes Mellitus and the risk of LEAD  
Nikolaos **Tentolouris**

Lp(a) and Thromboembolic Risk. Present and future  
Alexandros **Tselepis**

Reduction of ischemic events with the use of PCSK9 inhibitors.  
Results from recent clinical trials  
Evangelos **Liberopoulos**

## SCIENTIFIC PROGRAMME

Saturday, November 5<sup>th</sup>, 2022

20.00-21.00 **Keynote Lectures. Recent guidelines on antithrombotic management**

*Chairs:* Vittorio **Pengo (Italy)**, Ioanna **Andreadou**

2022 ACCP perioperative antithrombotic management guidelines  
James **Douketis**

2002 ISTH COVID anticoagulation guidelines  
Alex **Spyropoulos**

Sunday, November 6<sup>th</sup>, 2022

## 09.00-11.00 Pathogenesis of ischemic stroke: Heart and Vessels

*Chairs:* Christos **Savopoulos**, Athanassios **Protogerou**

Hypertension and ischemic stroke: from pathophysiology to effective management

Nikolaos **Kakaletsis**

Lp (a) and stroke: potential relationship, attributable risk and management

Matilda **Florentin**

PFO: to close or not to close?

Paraskevi **Savvari**

CAS vs. CAE: Pros and cons

Dimitrios **Nikas**

Thrombophilia and stroke: an innocent bystander?

Georgia **Kaifa**

---

11.00-11.30 **Break**

---

## 11.30-13.15 Challenging the risk and management of venous thromboembolism in Women

*Chair:* Minas **Paschopoulos**, Theodoros **Stefos**

*Moderators:* George **Farmakides**, Despoina **Adamidou**

Hormonal therapy and risk of thrombosis

Ploutarchos **Tzoulis**

Special issues regarding the Prophylaxis and Therapy of VTE in women of all ages

Eleftheria **Lefkou**

Post-thrombotic syndrome in women

Konstantinos **Konstantinides**

Thrombosis and Placenta

Vasileios **Papadopoulos**

---

13.15-13.30 **Discussion**

---

Saturday, November 5<sup>th</sup>, 2022

11.30-12.00 Satellite Lecture Pfizer



Chair: Dimitrios **Alexopoulos**

PCI/ACS and Atrial Fibrillation - Optimal Antithrombotic treatment

John **Kanakakis**

**Theracor**<sup>®</sup>  
bisoprolol fumarate

**Theracor plus**<sup>®</sup>  
bisoprolol fumarate + hydrochlorothiazide

Αλλάζουμε συνήθειες  
στη διαχείριση της  
Καρδιαγγειακής Νόσου



Pharmaceutical Laboratories S.A.

ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

**1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** THERACOR 5 mg επικαλυμμένο με λεπτό υμένιο δισκίο, THERACOR PLUS (10+25) mg, 1 επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 10 mg φουμαρικής βισοπρολόλης και 25 mg υδροχλωροθειαζιδίου. **3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Επικαλυμμένο με λεπτό υμένιο δισκίο. **4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ: Θεραπευτικές ενδείξεις:** THERACOR: Θεραπεία χρόνιας σταθερής καρδιακής ανεπάρκειας με μειωμένη συστολική λειτουργία της αριστεράς κοιλίας ως επιρόσφιξη θεραπείας με αναστολείς του μετασπαστικού ενζύμου της αγγειοτασίνης και διουρητικά, και προσωρινά καρδιακά γλυκοσίδες. THERACOR PLUS: Μικροθλής Υγίαση, Αποστολικά και τριπλός χορήγησης: Το δισκίο πρέπει να λαμβάνεται το πρωί και μπορούν να λαμβάνονται με τροφή. THERACOR: Η μέγιστη συνιστώμενη ημερήσια δόση είναι 10 mg βισοπρολόλης. THERACOR PLUS: Συνίσταται η ατομική titroadόση της δόσης με την κάθε ούρα ξεχωριστά. **Αντενδείξεις:** Οξεία καρδιακή ανεπάρκεια ή κατά τη διάρκεια επεισοδίων μη ανταρποποιούμενης καρδιακής ανεπάρκειας που απαιτούν ενδοφλέβια ενόσφιξη. Καρδιογενής καταπληξία (shock). **Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση:** Πρέπει να χρησιμοποιείται με προσοχή σε: βρογχόσπασμο (βρογχικό άσθμα, αποφρακτικές πνευμονοπάθειες), Σακχαρώδη διαβήτη που εμφανίζει μεγάλες διακυμάνσεις στις τιμές γλυκόζης αίματος, **Ανεπιθύμητες ενέργειες:** Βροδικαρδία, ζάλη, κεφαλαλγία, επιδείνωση, καρδιακή ανεπάρκεια, ναυτία, έμετος, διάρροια, δυσκοιλιότητα, εξασθένιση, ορθοστατική υπόταση, μείκη οδοντογμία, μαϊκές κρέματες.

THERACOR: Α.Τ. 3.35 €. THERACOR PLUS (10 + 25) mg: Α.Τ. 4.62 €.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αυτοφύρετο ΟΠΕΣ ως ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα.  
Σηματοδότηση στην "ΚΙΤΡΙΝΗ ΚΑΡΤΙΣ".

### A

**Almpanis Georgios**

Interventional Cardiologist at University Hospital of Patrai

**Andreadou Ioanna**

Professor, Section of Pharmaceutical Chemistry

**Adamidou Despina**

Consultant Haematologist, Hippokraton General Hospital, Thessaloniki

**Alexopoulos Dimitrios**

Professor of Cardiology, School of Medicine, National & Kapodistrian University of Athens, Second Department of Cardiology, Athens University General Hospital "ATTIKON"

**Andrikopoulos Georgios**

Assistant Professor, KTH Royal Institute of Technology

### B

**Badimon Lina**

Professor, Director, Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIBSant Pau, CiberCV, Barcelona, Spain, Member of the Board of the European Society of Cardiology 2020-2022, President of EMLTD Foundation - European Mediterranean League Against Thrombotic Diseases

**Bakola Eleni**

Consultant, 2nd Department of Neurology University Hospital "Attikon"

**Babali Theodora**

Assistant Curator, 2nd Department of Cardiology, Chest and Heart Department, Ioannina University Hospital

**Botis Michail**

MD, MSc, Cardiology Resident, 251 Hellenic Air Force General Hospital

**Bronic Anna**

Scientific Research Associate with interests in haemostasis, haematology, and molecular diagnostics. Specialist in medical biochemistry and laboratory medicine at the Department for laboratory diagnostics in traumatology and orthopaedics. Clinical Institute of Chemistry, Medical School University Hospital "Sestre Milosrdnice", Zagreb, Croatia. Head of Working Group for laboratory coagulation in CSMBLM that include continuous work on the development, improvement, and implementation procedures for laboratory haemostasis.

### D

**Demir Muzaffer**

Professor Doctor » In 2007, Trakya University Faculty of Medicine

**Douketis James**

Professor, Department of Medicine, McMaster University, Hamilton, Canada

**Dimakakos Evangelos**

Vascular Internist, Head of Vascular Unit-Training Center of Angiology of UEMS- of 3rd Department of Internal Medicine of University of Athens Public Hospital 'SOTIRIA' Director of Center of Prevention, Diagnosis and Treatment of Lymphedema -Lymphatic Diseases of Metropolitan Hospital Athens, Greece Elected President of International Society of Lymphology President of World Congress of Lymphology ISL 2021 28th World Congress of Lymphology (isl2021lymphology.com) Greek Delegate of UEMS of Angiology / Vascular Medicine Vice President of Scientific Committee of European Society of Lymphology Member of the International- European & Greek Society of Angiology-Lymphology



## INDEX / INVITED FACULTY

## E

**Elalamy Ismail**

Professor of Hematology and Director of Hematology Department of Thrombosis Center, CHU Tenon, France

**Ellul John**

Professor of Neurology, Faculty of Medicine, School of Health Sciences, University of Patras

## F

**Farmakides George**

Professor ob-gyn,mfm, stony brook university,usa, treasurer of hsmfm

**Florentin Matilda**

Medical doctor, Department of Internal Medicine, Faculty of Medicine, School of health Science, University of Ioannina

## G

**Girtovitis Fotios**

AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

**Gianoukas Athanasios**

Professor of Vascular Surgery, Faculty of Medicine, University of Thessaly, Greece.

**Glantzounis Georgios**

Surgeon, Professor of Surgery-Transplants, Faculty of Medicine, School of Health Sciences, University of Ioannina

**Goudevenos John**

Emeritus Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina

**Grouzi Elissavet**

Consultant of Hematology, Head of Transfusion Service and Clinical Haemostasis, "St Savvas" Oncology Hospital, Athens, Greece

## I

**Ieronimos**

Respected Metropolitan of Kalavrita

## K

**kaiafa Georgia**

Assistant Professor, 1st Educational Pathology Clinic, Faculty of Medicine, Aristotle University of Thessaloniki

**Kakaletsis Nikolaos**

MD, MSc (ESO Stroke Medicine), PhD, Internist, Second Medical Department, Ippokratio General Hospital, Aristotle University of Thessaloniki, Postdoctoral Researcher, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

**Kalantzi Kalliroti**

Cardiologist, Dr of University of Ioannina

**Kanakakis John**

Head of Hemodynamic Department, General Hospital of Athens "Alexandra", President of Hellenic Society of Cardiology

**Kargiotis Odyseas**

Neurologist - Curator, Metropolitan Hospital Athens

**Katsouras Christos**

Associate Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina

**Kiriakou Elias**

Hematologist, Curator of Hematology Laboratory & Blood Donation Service, Athens University General Hospital "ATTIKON"

**Kochiadakis Georgios**

Dean of Medical School, University of Crete, Professor of Cardiology, Vice President of the Hellenic Society of Cardiology

### **Konstantinidis Konstantinos**

Vascular Surgeon, Thessaloniki, Greece

### **Koromboki Eleni**

Curator of Internal Medicine, Department of Clinical Therapeutics, Alexandra General Hospital of Athens

### **Katsouras (Κατσούρας) Christos**

Associate Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina

### **Koulas Ioannis**

MD, MSc Post Doctoral Research Trainee, Anticoagulation and Clinical Thrombosis Services, Institute of Health System Science Feinstein Institutes for Medical Research

### **Kozak Matija**

MD, PhD, University Medical Centre Ljubljana, Department for Vascular Diseases, SLOVENIA

## L

### **Lefkou Eleftheria**

Curator Haematologist, Specialised in Haemostasis & Thrombosis, Obstetric Haematology, Antiphospholipid Syndrome

### **Liberopoulos Evangelos**

Associate Professor of Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina

## M

### **Milionis Haralampos**

Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina

### **Morais Joao (Portugal)**

Cardiologist, Professor in Oporto Medical School, Head of the Cardiology Division Leiria Hospital Centre, Portugal

## N

### **Nikas Dimitrios**

MD, MSc, PhD, FESC, Interventional Cardiologist, Cardiology Department, University General Hospital of Ioannina, Greece

### **Nomikos Tzortzis**

MSc, PhD, Associate Professor, Director of the Postgraduate Studies, School of Health Sciences and Education, Department of Nutrition and Dietetics Harokopio University

### **Nomikou Efrosyni**

Hematologist, Director, National Health Care System of Blood Donation, Department of Haemophiliac, "Hippokraton" General Hospital, Athens

### **Ntaios Georgios**

MD, MSc (ESO Stroke Medicine), PhD, FESO, Associate Professor of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly

## P

### **Palaiodimou Lina**

Neurologist, Second Department of Neurology, "Attikon"

### **Panagiotakos Demosthenes**

Professor in Biostatistics, Research Methods and Epidemiology at Harokopio University in Athens, Greece

### **Papadopoulos Athanasios**

Mayor of Kalavryta

### **Papadopoulos Vasileios**

Associate professor ob-gyn, mfm, university of patras, member of hsmfm

### **Papanagiotou Panagiotis**

Associate Professor of Radiology, National & Kapodistrian University of Athens, Professor of Neuroradiology, Bremen-Mitte Hospital, Germany

## INDEX / INVITED FACULTY

### **Pappas Apostolos**

Marketing Manager Cardiometabolics

### **Paschopoulos Minas**

Professor of Obstetrics – Gynecology, Head of Obstetrics - Gynecology Clinic, Faculty of Medicine, School of Health Sciences, University of Ioannina, Vice Rector of the University of Ioannina

### **Pattakos Stratis**

Director cardiac Surgery Hygeia Hospital

### **Pattakos Gregoris**

Medical Doctor, MSc Student at Aristotle University of Thessaloniki (AUTH), Hellenic Air Force Officer

### **Pengo Vittorio**

Professor of Cardiovascular Medicine (senior scientist), Thrombosis Research Laboratory, University of Padova, Bologna, Italy

### **Philippatos Theodosios**

Assistant Professor of Internal Medicine, Metabolic Diseases Research Unit, Internal Medicine Laboratory, School of Medicine, University of Crete

### **Pipilis Athanasios**

Cardiologist, Consultant, First Department of Cardiology, "Hygeia" Diagnostic and Therapeutic Centre of Athens

### **Protogerou Athanassios**

MD, PhD, Professor of Pathological Physiolog, Head of the Cardiovascular Prevention & Research Unit, Clinic & Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens

## R

---

### **Richter Dimitrios**

Cardiologist, Director of Cardiology Clinic, "Euroclinic" Athens

## S

---

### **Sagris Dimitrios**

Internist - Clinical Research Fellow, Department of Medicine and Research Laboratory, University of Thessaly, Larissa University Hospital

### **Savopoulos Christos**

Professor of Internal Medicine, Director of 1st Medical Propedeutic Dept of Internal Medicine & Stroke Unit, Aristotle University of Thessaloniki, AHEPA University Hospital

### **Savvari Paraskevi**

Senior Medical Manager, IM, Pfizer Hellas

### **Spanos Anastasios**

MD, PhD, FESC, FSCAI, Rear Admiral - Cardiologist, Former Director of Cardiology Clinics, Navy Hospital of Athens, Director of Cardiology Department, Athens Medical Center & Euroclinic of Athens

### **Stefos Theodoros**

Professor ob-gyn, mfm, university of ioannina, president of hsmfm

### **Spyropoulos Alex (USA)**

Professor of Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Professor - The Institute for Health Innovations and Outcomes Research - The Feinstein Institutes for Medical Research, System Director – Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital

## T

---

### **Tentolouris Nikolaos**

Professor of Medicine, 1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens

## INDEX / INVITED FACULTY

### **Tselepis Alexandros**

Professor of Biochemistry - Clinical Chemistry, Department of Chemistry, University of Ioannina

### **Tsiara Stavroula**

Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina

### **Tsoukalas Nikos**

MD, MSc, PhD, medical oncologist, Aristotle University of Thessaloniki

### **Tsivgoulis Georgios**

Professor of Neurology, School of Medicine, National & Kapodistrian University of Athens, Second Department of Neurology, Athens University General Hospital "ATTIKON"

### **Tzeis Stylianos**

Head of Cardiology Department and Electrophysiology & Cardiac Pacing Section in Mitera Hospital, Hygeia Group

### **Tsiara Stavroula**

Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina

### **Tzoulis Ploutarchos**

MD, PhD, FRCP (Lon), MSc (Hons), CCT (UK) Hon. Associate Professor in Endocrinology, UCL (University College London) Medical School Consultant in Endocrinology, Diabetes & General Internal Medicine

## V

---

### **Vardas Panos**

Professor of Cardiology, University of Crete

### **Varon David**

Hematology Blood and Marrow Transplant

### **Vemmos Konstantinos**

Pathologist, Stroke Specialist, Hellenic Society of Cardiology

**Ivor**<sup>®</sup>  
Bemiparin sodium

**IvorMAX**<sup>®</sup>  
Bemiparin sodium



**ΣΥΝΟΠΤΙΚΗ ΠΕΡΙΓΡΑΦΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ**

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivor 2.500 IU anti-Xa/0,2 ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 2.500 IU (anti Factor Xa\*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 12.500 IU (anti Factor Xa\*) ανά ml ενέσιμο διάλυμα). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1.

**ΣΥΣΚΕΥΑΣΙΣ/ΤΙΜΕΣ:** IVOR 2.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR Λ.Τ.: 5,83 €

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivor 3.500 IU anti-Xa/0,2 ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 3.500 IU (anti Factor Xa\*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 17.500 IU (anti Factor Xa\*) ανά ml ενέσιμο διάλυμα). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1.

**ΣΥΣΚΕΥΑΣΙΣ/ΤΙΜΕΣ:** IVOR 3.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR Λ.Τ.: 10,74 € BT x 30 PF.SYR Λ.Τ.: 120,83 €

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivormax 25.000 IU anti-Xa/ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 25.000 IU (anti-Factor Xa\*) ανά ml ενέσιμο διάλυμα. Ισοδύναμη με: 5.000 IU (anti-Factor Xa) ανά 0,2 ml προγεμισμένη σύριγγα, 7.500 IU (anti-Factor Xa) ανά 0,3 ml προγεμισμένη σύριγγα, 10.000 IU (anti-Factor Xa) ανά 0,4 ml προγεμισμένη σύριγγα. \* Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΣ/ΤΙΜΕΣ:** IVORMAX 25.000 IU anti-Xa/ml, BTx2PF.SYRx0,2ML Λ.Τ.: 21,86€, IVORMAX 25.000 IU anti-Xa/ml, BTx2PF.SYRx0,3ML Λ.Τ.: 19,09€, IVORMAX 25.000 IU anti-Xa/ml BTx2PF.SYRx0,4ML Λ.Τ.: 23,33€

**ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Ενέσιμο διάλυμα σε προγεμισμένες σύριγγες. (Άχρωμο ή ελαφρώς κτρινωπό, διαυγές διάλυμα, ελεύθερο ορατών σωματιδίων). **ΚΑΤΟΧΟΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** ΒΙΑΝΕΞ Α.Ε. – Οδός Τατσιού, 146 71 Νέα Ερυθραία, Τηλ. 210 8009111.

**ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** 12-10-2021

**ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ:** Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή  
Περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ κατόπιν αιτήσεως.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



**BIANEX** A.E.  
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ  
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

BIANEX A.E. - Έδρα : οδός Τατσιού, 18<sup>ο</sup> χλμ. Ε.Ο. Αθηνών – Λαμίας 146 71 Ν. Ερυθραία Αττικής, Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία  
Τηλ. : 210 8009111 • Fax: 210 8071573 • E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr  
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδημίου 113, 562 24 Εύοσμος Θεσσαλονίκης Τηλ.: 2310 861683

ΑΡ. Γ.Ε.ΜΗ. 000274201000



VE-22096-IVO-4/2022



# Liptruzet®

(ezetimibe and atorvastatin) tablets

Ο **μόνος\*** σταθερός συνδυασμός

εξετιμίμης/ατορβαστατίνης

με εγκεκριμένη ένδειξη

στη **Πρόληψη των Καρδιαγγειακών Επεισοδίων<sup>1</sup>**

#### 4. ΚΛΙΝΙΚΕΣ ΠΑΗΡΟΦΟΡΙΕΣ

##### 4.1 Θεραπευτικές ενδείξεις

###### Πρόληψη των Καρδιαγγειακών Επεισοδίων

Το LIPTRUZET ενδείκνυται για τη μείωση του κινδύνου των καρδιαγγειακών επεισοδίων (βλ. παράγραφο 5.1) σε ασθενείς με στεφανιαία νόσο (ΣΝ) και με ιστορικό οξέος στεφανιαίου συνδρόμου (ΟΣΣ), που είτε έχουν λάβει προηγούμενη θεραπεία με στατίνη είτε όχι.

1. ΠΧΠ LIPTRUZET\_31\_08\_2021

\* Σύμφωνα με τις ΠΧΠ των κυκλοφορούντων σταθερών συνδυασμών εξετιμίμης/ατορβαστατίνης στην Ελλάδα

Πριν τη συνταγογράφηση συμβουλευτείτε την περιλήψη χαρακτηριστικών του προϊόντος.

LIPTRUZET® (10+10) MG/TAB | ΛΤ: 42,81€,  
LIPTRUZET® (10+20) MG/TAB | ΛΤ: 40,92€,  
LIPTRUZET® (10+40) MG/TAB | ΛΤ: 40,56€.



Τοπικός Αντιπρόσωπος:  
BIANEX A.E. - Έδρα : οδός Τατόιου, 18<sup>ο</sup> χλμ. Ε.Ο. Αθηνών – Λαμίας,  
146 71 Ν. Ερυθραία Αττικής, Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία,  
Τηλ. : 210 8009111 • Φαξ: 210 8071573  
E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr  
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδήμίου 113, 562 24 Εύοσμος Θεσσαλονίκης, Τηλ.: 2310 861683

ΑΡ. Γ.Ε.ΜΗ. 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και αποτελεσματικά  
ΟΛΕΣ τις συσκευασίες ενδείκνυται για όλα τα φάρμακα Συμπληρώνοντας την «LIPTRIN KART»



Κάτοχος Άδειας Κυκλοφορίας :  
N.V. Organon, Kloosterstraat 6,  
5349 AB Oss,  
Ολλανδία.

## GENERAL INFORMATION

### ■ DATE & VENUE

The **Advanced Learning on Platelets and Thrombosis International Course (ALPIC 2022)** is held from **Friday, November 4<sup>th</sup>** to **Sunday, November 6<sup>th</sup> 2022** in Kalavrita, Greece, at Kalavrita Canyon Hotel.

The **ALPIC 2022** will be realized in Kalavrita Canyon Hotel, a 4\* hotel situated in **Kalavrita**, Achaia region of Peloponnese, Greece. In the heart of the beautiful and historic town of Kalavrita, **ALPIC 2022** will be actualized in the hotel's Conference Halls. The Conference will be conducted in a hybrid manner (with physical presence of a number of participants and simultaneous on Digital Broadcast). In case, for epidemiological reasons, the conference cannot be held with physical presence, it will be held entirely online.

### ■ ABOUT KALAVRITA

Kalavrita is a town in the mountainous east-central part of the regional unit of Achaia in Peloponnese, Greece. The town is located 24 kilometres south of Aigio and 40 km southeast of Patras. Kalavrita is surrounded by beautiful mountains Erymanthos in the west and Chelmos in the southeast.

Kalavrita area brings together a large number of attractions of historical and religious significance and natural beauty. The Vouraikos Canyon is among the Global Network of Geoparks, which was established under the auspices of UNESCO, and a geological monument of world heritage. This natural richness of the Greek geological heritage can be admired in a magical journey with **the cog of Kalavrita**. The **Cave of the Lakes** is also a work of nature worth to visit just minutes away from the town of Kalavryta. In the **Monastery of the Great Cave** you can admire one of the four projects of the Evangelist Luke, the embossed image of the Virgin Chrysospilotissa while **Holy Agia Lavra Monastery** holds the first place as a national-religious pilgrimage and is a unique historical monument. The **Museum of the Holocaust** the historic Elementary school which houses the history and the memory of the 1943 drama in Kalavrita. The **Place of Sacrifice** is located a few meters outside the city, the sacred place where the massacre of Kalavryta took place. The destination of Kalavryta is ideal for those who love nature and sports suitable for all seasons. The activities vary according to your desire and mood. During winter time, snow lovers have the opportunity to enjoy **the snowy ski resort** to take a walk or indulge in their favorite activities such as ski, snowboard, ski mobiles. During the other seasons of the year however, the proposed activities are numerous.

A large number of trails of all difficulty levels, suitable for **Hiking and Mountaineering**, that all have something in common: the opportunity to admire the unique beauty of the Greek nature. These images of nature can also be admired by anyone engaged in sports in the river **Ladon kayaking or rafting**. A few adventurous have the opportunity to gaze nature from above by **paragliding**.

For those seeking the coolness combined with trips to the beach during the summer, Kalavrita is a destination located just 30 minutes away from two **beaches** with crystal-clear waters.

### ■ LANGUAGE

The official languages of the Course are **Greek** and **English**. The English language may be used widely especially in the presentations of the speakers to encourage the interaction in all scientific sessions of the English speaking faculty.

### ■ REGISTRATIONS

#### **Registration Fee: 200.00 euros + 24% VAT**

Registration Fee includes:

- Access to Conference & exhibition area
- Conference material (e-program & e-badge & codes for digital access)
- e-Certificate of attendance
- Attendance at the organized Coffee breaks during the Scientific Program

#### **Digital Registration Fee: 50.00 euros + 24% VAT**

Digital Registration Fee includes:

- Access to digital Conference
- Conference material (e-program & codes for digital access)
- e-Certificate of attendance

### ■ CREDITS

The Congress will be accredited with 21 C.M.E. Credits by the Panhellenic Medical Association.

### ■ CERTIFICATE OF ATTENDANCE

Continuing Medical Education Credits will be awarded by the Panhellenic Medical Association. All registered to the Course will have their e-badge and codes (username and password) for digital access that will count the time of attendance (physically or virtually). Each (1) credit of Continuing Medical Education corresponds to one full hour attendance. Participants can download their Certificates 2 dates after the end of the Course from the site of Congress World <https://certificates.congressworld.gr/gr/congress>.

### ■ CONTACT



#### **Congress World**

27, Michalakopoulou Ave, 115 28, Athens Greece  
Tel: +30 (210) 7210001, 7210052, 7222518, 7210025  
E-mail: [info@congressworld.gr](mailto:info@congressworld.gr), [ea@congressworld.gr](mailto:ea@congressworld.gr)  
[www.congressworld.gr](http://www.congressworld.gr)



## SPONSORS

The Organizers wish to thank the following pharmaceutical companies for their support in the accomplishment of the Course:



**Bayer**



**BIANEE** A.E.  
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ  
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ



**Boehringer  
Ingelheim**



**VIATRIS**



**Pharmaceutical Laboratories S.A.**



PP-XAR-GR-0461-1  
02.2022



Κάτοχος της άδειας κυκλοφορίας:  
Bayer AG, 51368 Leverkusen, Γερμανία.  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς  
ΑΒΕΕ, Σωρού 18-20, 151 25 Μαρούσι.  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Κύπρο: Novagem Ltd,  
Τηλ: 00357 22483858.  
**Τμήμα Επιστημονικής Ενημέρωσης**  
Τηλ: +30 210 6187742, Fax: +30 210 6187522  
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπροώθησης



**ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ**  
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,  
Τηλ: 210 6039326 - 9, Fax: 210 6039300  
**ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ**  
Σεβαστείας 11, 115 28 Αθήνα,  
Τηλ: 210 7488711, Fax: 210 7488731  
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,  
Τηλ: 2310 459920 - 1, Fax: 2310 459269



**Xarelto**<sup>®</sup>  
rivaroxaban

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»»